Source - LSE Regulatory
RNS Number : 7572O
Advanced Oncotherapy PLC
01 February 2019

1 February 2019



("Advanced Oncotherapy" or the "Company")


Appointment of Nominated Adviser and Joint Broker

Advanced Oncotherapy (AIM: AVO), the developer of a next-generation proton therapy system for cancer treatment, is pleased to announce the appointment of Allenby Capital Limited as the Company's nominated adviser and joint broker with immediate effect.

For further information, please contact:

Advanced Oncotherapy Plc

Tel: +44 (0) 20 3617 8728

Dr. Michael Sinclair, Executive Chairman

Nicolas Serandour, CEO

Allenby Capital Limited  (Nominated Adviser & Joint Broker)

Tel: +44 (0) 20 3328 5656

Nick Athanas / Liz Kirchner / Nicholas Chambers

Stifel Nicolaus Europe (Joint Broker)

Tel: +44 (0) 20 7710 7600

Jonathan Senior

Walbrook PR (Financial PR & IR)

Paul McManus / Anna Dunphy

Tel: +44 (0) 20 7933 8780

Mob: +44 (0) 7980 541 893

Mob: +44 (0) 7876 741 001


About Advanced Oncotherapy Plc

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.